All In Biotech

Drug Trial Radar · NCT05874401

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

302

Planned (sponsor's estimate)

Start

Oct 13, 2023

Primary completion

Feb 5, 2028

Study completion Feb 5, 2028

Sponsor

Lead sponsor
Pharmacosmos A/SIndustry
Sponsor type
Industry
First posted
May 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.

Conditions

  • Extensive-stage Small-cell Lung Cancer

Interventions

  • TrilaciclibDrug

    Participants will receive intravenous trilaciclib infusion

  • PlaceboDrug

    Participants will receive intravenous placebo infusion

  • TopotecanDrug

    Participants will receive intravenous topotecan infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From date of randomization until date of death due to any cause for those who died; or date of last contact known as alive for those who survived in the study (censored cases), assessed up to 52 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.